Compare Sony Group Corp (SONY) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sony Group Corp vs Vertex Pharmaceuticals Incorporated — how do they compare? Sony Group Corp trades at $24.03 (market cap $136.87B), while Vertex Pharmaceuticals Incorporated trades at $503.25 (market cap $127.55B). The key difference: Sony Group Corp and Vertex Pharmaceuticals Incorporated are close in size by market cap, and Sony Group Corp pays a 0.66% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals — on Pluang, investors hold Sony Group Corp for 96 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| SONY | VRTX | |
|---|---|---|
Market Cap | $136.87B | $127.55B |
Volume | 5,364,503 | 1,487,944 |
Sector | Technology | Health |
52-Week High | $30.26 | $557.96 |
52-Week Low | $19.32 | $407.37 |
Typical Hold Time | 96 Days | 120 Days |
Enterprise Value | $134.77B | $121.68B |
Dividend Yield | 0.66% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Sony trades at $23.52, down 1.38% on the day, with mixed technical signals showing a neutral overall trend. The company reported strong Q4 2025 and Q2 2026 earnings beats but missed Q1 2026 expectations. Revenue remains stable around $12.96T with solid gross margins of 31.82%, though net income margin turned negative at -1.75% for 2026. Analyst sentiment remains bullish with 11 buy ratings versus 5 holds.
Sony presents a compelling value case with reasonable valuation multiples (P/E 19.93, P/S 1.75) and strong cash flow generation. However, recent negative profitability metrics and the Q1 2026 earnings miss highlight execution risks. The company's diversified entertainment portfolio and AI positioning offer growth potential, but investors should monitor margin recovery and content performance.
Vertex Pharmaceuticals (VRTX) trades at $505.64, up 0.63% on the day, with a bearish technical signal despite a neutral oscillator reading. The company reported strong 2025 revenue of $12.00B and net income of $3.95B, with a net margin of 35%. Recent positive Phase 2b data for its kidney disease drug inaxaplin highlights pipeline expansion beyond cystic fibrosis dominance. Analyst consensus is strongly bullish with an 83.9% buy rating and a $573.50 price target, implying 13.4% upside.
The outlook for VRTX is positive, driven by its profitable core business and promising pipeline, but faces risks from clinical trial outcomes and competitive pressures. The stock's current valuation at a P/E of 29.45 is reasonable given its growth prospects, though investors should monitor execution on new drug approvals and market adoption.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Sony Group Corp
Sony Group is a conglomerate with consumer electronics roots, which not only designs, develops, produces, and sells electronic equipment and devices, but also is engaged in content businesses, such as console and mobile games, music, and movies. Sony is a global top company of CMOS image sensors, game consoles, professional broadcasting cameras, and music publishing, and is one of the top players on digital cameras, wireless earphones, recorded music, movies, and so on. Sony's business portfolio is well diversified with six major business segments. The company fully consolidated Sony Financial in September 2020, which provides life and non-life insurance, banking, and other financial services.
Read more on SONY →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
